AF721
antibody from R&D Systems
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF721 - Provider product page
- Provider
- R&D Systems
- Product name
- Mouse TRAIL R2/TNFRSF10B Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects mouse TRAIL R2 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) TRAIL R2 is observed.
- Reactivity
- Mouse
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q6GSD9
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Shekhar TM, Miles MA, Gupte A, Taylor S, Tascone B, Walkley CR, Hawkins CJ
Oncotarget 2016 Jun 7;7(23):33866-86
Oncotarget 2016 Jun 7;7(23):33866-86
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R
Blood 2009 Jun 11;113(24):6120-7
Blood 2009 Jun 11;113(24):6120-7
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Biochemical pharmacology 2006 Jul 28;72(3):293-307
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cytotoxicity Induced by TRAIL/TNFSF10 and Neutralization by Mouse TRAIL R2/TNFRSF10B Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induces cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, cytotoxicity elicited by Recombinant Human TRAIL/TNFSF10 (12 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse TRAIL R2/TNFRSF10B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF721). The ND50 is typically 0.4-1.2 µg/mL.